Link Between Glucosamine Use and Accelerated Alzheimer’s Disease Progression

Recent findings from the University of Florida suggest a concerning connection between glucosamine supplements, commonly used for joint pain, and the acceleration of Alzheimer's progression. This research, published in Nature Metabolism on June 9, highlights that patients with mild cognitive impairment (MCI) who take glucosamine may have a higher chance of developing dementia than those who do not.

In this study, researchers utilized a combination of health record analysis and advanced imaging techniques to analyze human brain tissue and mouse models affected by Alzheimer's. About 1,896 patients with Alzheimer's-related dementias (ADRD) and 2,750 MCI patients reported glucosamine use, representing roughly 8% of each group. Even after adjusting for age, gender, and other demographics, the results indicated that glucosamine users among the MCI cohort exhibited a 25% increased likelihood of progressing to dementia, alongside a similar mortality risk increase in ADRD patients.

Dr. Ramon Sun, the study's senior author and director of the Center for Advanced Spatial Biomolecule Research, pointed out the potential implications of these findings. "In the United States, approximately 7 million individuals suffer from Alzheimer's and millions more have related forms of dementia. Many might be unwittingly exacerbating their conditions by consuming an over-the-counter supplement," he stated.

Investigating the Biological Impact

This research was particularly motivated by concerns regarding glucosamine's metabolic effects. The study found that glucosamine could interfere with specific biological processes in the brain that are already disrupted in Alzheimer's. The team’s analysis identified that a protein and sugar-tagging pathway may be excessively active in Alzheimer's patients, suggesting a possible new target for future treatments.

"Our findings imply that metabolic dysfunction is a significant contributor to the advancement of Alzheimer's," Sun noted. "Addressing these metabolic issues could complement treatments aimed at decreasing Alzheimer's plaques and tangles." Advances in spatial analysis technology, developed in Sun's lab, enabled researchers to investigate thousands of molecules associated with metabolic breakdown in the body.

Glucosamine's Dual Role in Disease Progression

Specifically, glucosamine is noteworthy because it can cross the blood-brain barrier and contribute to biochemical pathways that build sugar structures on proteins. Often derived from shellfish shells or corn, glucosamine's effects may vary significantly based on the biological context it encounters in the brain.

Co-author Dr. Matt Gentry, chair of the Department of Biochemistry and Molecular Biology at UF, remarked on the provocative nature of the health record data. While the results indicate a correlation rather than a causal relationship, they raise critical clinical questions deserving further exploration. He noted that the Alzheimer’s-affected brain may be particularly vulnerable to disturbances in the protein sugar-tagging pathway.

Animal Model Insights

Supporting the human data, experiments in genetically modified mice revealed that glucosamine significantly enhanced sugar molecule attachment to proteins. Mice treated with the supplement exhibited deterioration in social memory capabilities, which reflect the ability to recognize and remember other individuals. In contrast, reducing this sugar-tagging activity improved their memory performance.

Examining human brain tissue from the UF Neuromedicine Brain and Tissue Bank, researchers also found elevated levels of sugar attachment in Alzheimer's specimens compared to healthy controls, reinforcing the idea that metabolic abnormalities may play a contributing role in the disease rather than merely being a byproduct.

Gentry explained, "Proteins function as molecular machines within cells, and their proper activation often depends on the right sugar attachments. In Alzheimer's, our results illustrate an overactive sugar-tagging process, contributing to disease pathology instead of a protective mechanism."

As research progresses, understanding glucosamine's exact role in Alzheimer's disease will be essential. The study underscores the need for further clinical trials to determine whether glucosamine should be reconsidered in treatment protocols for individuals at risk of or living with Alzheimer's disease.

Materials provided by UF Health. Note: Content may be edited for style and length.